• Catheter Precision, wholly owned by Flyte Aviation, received FDA 510(k) clearance for expanded use of its VIVO system.
• The clearance extends VIVO use to patients with structural heart disease undergoing catheter ablation for monomorphic ventricular tachycardia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Flyte Aviation Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020800PRIMZONEFULLFEED9867708) on November 02, 2026, and is solely responsible for the information contained therein.